IV immunoglobulin in patients with myasthenia gravis

Zinman, Lorne; Ng, Eduardo; Bril, Vera

doi:10.1212/01.wnl.0000256698.69121.45

Cited by 252 publications

(196 citation statements)

References 19 publications

Supporting

Mentioning

177

Contrasting

Unclassified

Order By: Relevance

“…PLEX effectively improves strength in most patients with severe MG [46,47]. IVIg is widely used for patients with exacerbating MG. Randomized controlled trials that show efficacy similar to PLEX [46], and a double-blind, placebo-controlled trial in patients with MG with worsening weakness [48], support its use in the clinic. Randomized controlled trials comparing IVIg with plasmapheresis have shown no significant differences between the two in treatment of an acute MG exacerbation [49], but PLEX may have a faster onset of action and is the treatment of choice in MG crisis.…”

Section: Present Management Of Autoimmune Mgmentioning

confidence: 84%

Current Treatment, Emerging Translational Therapies, and New Therapeutic Targets for Autoimmune Myasthenia Gravis

2016

View full text Add to dashboard Cite

Myasthenia gravis (MG) is an autoimmune disease associated with the production of autoantibodies against 1) the skeletal muscle acetylcholine receptor; 2) muscle-specific kinase, a receptor tyrosine kinase critical for the maintenance of neuromuscular synapses; 3) low-density lipoprotein receptor-related protein 4, an important molecular binding partner for muscle-specific kinase; and 4) other muscle endplate proteins. In addition to the profile of autoantibodies, MG may be classified according the location of the affected muscles (ocular vs generalized), the age of symptom onset, and the nature of thymic pathology. Immunopathologic events leading to the production of autoantibodies differ in the various disease subtypes. Advances in our knowledge of the immunopathogenesis of the subtypes of MG will allow for directed utilization of the ever-growing repertoire of therapeutic agents that target distinct nodes in the immune pathway relevant to the initiation and maintenance of autoimmune disease. In this review, we examine the pathogenesis of MG subtypes, current treatment options, and emerging new treatments and therapeutic targets.

show abstract

Section: Present Management Of Autoimmune Mgmentioning

confidence: 84%

Current Treatment, Emerging Translational Therapies, and New Therapeutic Targets for Autoimmune Myasthenia Gravis

2016

View full text Add to dashboard Cite

show abstract

“…A randomized placebo controlled trial reported the efficacy of intravenous immunoglobulins in worsening Myasthenia Gravis patients; the primary outcome was the Quantitative MG Score (QMG) assessed at baseline and at 14 and 28 days. Improvement was statistically significant at 14 days while the Quantitative MG Score at 28 days failed to reach statistic significance (Zinman et al, 2007).…”

Section: High Dose Intravenous Immunoglobulinsmentioning

confidence: 82%

“…Moreover, the controlled study reported by Zinman and coworkers (Zinman et al, 2007) included patients with muscle specific tyrosine kinase-associated Myasthenia Gravis; even though the results were not given for each antibody subgroup, the overall results indicate improvement also in patients without anti-acetylcholine receptor antibodies. This is particularly important for muscle specific tyrosine kinase-positive Myasthenia Gravis in case of respiratory insufficiency, when TPE is not available or not feasible.…”

Section: High Dose Intravenous Immunoglobulinsmentioning

confidence: 99%

Immunomodulatory Treatments for Myasthenia Gravis: Plasma Exchange, Intravenous Immunoglobulins and Semiselective Immunoadsorption

Baggi¹,

Antozzi²

2012

A Look Into Myasthenia Gravis

View full text Add to dashboard Cite

“…The usefulness of IVIG is best proved for GBS, in which several RCTs find IVIG and plasmapheresis to be equally efficacious [368]. IVIG is also beneficial in the treatment of myasthenic crisis, an approach that is supported by a single randomized trial [369]. Results from randomized trials comparing the efficacy of IVIG and plasmapheresis in myasthenia exacerbations are equivocal [288].…”

Section: Intravenous Immunoglobulinmentioning

confidence: 99%

Immune Mediated Diseases and Immune Modulation in the Neurocritical Care Unit

Geldern¹,

McPharlin

Becker

2012

Neurotherapeutics

View full text Add to dashboard Cite

This chapter will review the spectrum of immunemediated diseases that affect the nervous system and may result in an admission to the neurological intensive care unit. Immunomodulatory strategies to treat acute exacerbations of neurological diseases caused by aberrant immune responses are discussed, but strategies for long-term immunosuppression are not presented. The recommendations for therapeutic intervention are based on a synthesis of the literature, and include recommendations by the Cochrane Collaborative, the American Academy of Neurology, and other key organizations. References from recent publications are provided for the disorders and therapies in which randomized clinical trials and large evidenced-based reviews do not exist. The chapter concludes with a brief review of the mechanisms of action, dosing, and side effects of commonly used immunosuppressive strategies in the neurocritical care unit.

show abstract

IV immunoglobulin in patients with myasthenia gravis

Abstract: This study provides level 1 evidence for the effectiveness of IV immunoglobulin in patients with worsening weakness due to myasthenia gravis.

Cited by 252 publications

References 19 publications

Current Treatment, Emerging Translational Therapies, and New Therapeutic Targets for Autoimmune Myasthenia Gravis

Current Treatment, Emerging Translational Therapies, and New Therapeutic Targets for Autoimmune Myasthenia Gravis

Immunomodulatory Treatments for Myasthenia Gravis: Plasma Exchange, Intravenous Immunoglobulins and Semiselective Immunoadsorption

Immune Mediated Diseases and Immune Modulation in the Neurocritical Care Unit

Contact Info

Product

Resources

About